Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 3

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 3
---
 16 |
| (3) Condensed Interim Consolidated Statements of Financial Position           |     | 17 |
| (4) Condensed Interim Consolidated Statements of Changes in Equity            |     | 19 |
| (5) Condensed Interim Consolidated Statement of Cash Flows                    |     | 21 |
| (6) Notes to Condensed Interim Consolidated Financial Statements              |     | 23 |
| (Significant Uncertainty Regarding Going Concern Assumption)                  |     | 23 |
| (Material Accounting Policies)                                                |     | 23 |
| (Operating Segment Information)                                               |     | 23 |
| (Significant Changes in Equity Attributable to Owners of the Company)         |     | 23 |
| (Significant Subsequent Events)                                               |     | 23 |
| [Financial Appendix]                                                          |     |    |

<div align='center'>1</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

1. Financial Highlights for the Nine-month Period Ended December 31, 2024

### (1) Business Performance
(i) Consolidated Financial Results (April 1 to December 31, 2024)

|                                                                                  |     |                  |     |          |     |           |     |          |     |          |     |        |     |       |   |     |     |       | Billion JPY or percentage |
|                                                                                  |     | FY2023 Q3        |     |          |     | FY2024 Q3 |     |          |     | AER      |     |        |     |       |   | CER |     |       |                           |
|                                                                                  |     | Amount of Change |     |          |     | % Change  |     |          |     | % Change |     |        |     |       |   |     |     |       |                           |
| Revenue                                                                          |     |                  |     |  3,212.9 |     |           |     |  3,528.2 |     |          |     |  315.3 |     |   9.8 | % |     |     |   4.5 | %                         |
| Cost of sales                                                                    |     |                  |     | -1,044.2 |     |           |     |